nodes	percent_of_prediction	percent_of_DWPC	metapath
Bimatoprost—Madarosis—Vismodegib—skin cancer	0.0929	0.16	CcSEcCtD
Bimatoprost—Hair growth abnormal—Vismodegib—skin cancer	0.0929	0.16	CcSEcCtD
Bimatoprost—PTGER3—Prostanoid ligand receptors—PTGER4—skin cancer	0.0323	0.0934	CbGpPWpGaD
Bimatoprost—PTGFR—Prostanoid ligand receptors—PTGER4—skin cancer	0.0241	0.0698	CbGpPWpGaD
Bimatoprost—PTGER1—Prostanoid ligand receptors—PTGER4—skin cancer	0.0236	0.0684	CbGpPWpGaD
Bimatoprost—PTGER3—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.0215	0.0621	CbGpPWpGaD
Bimatoprost—PTGER3—Small Ligand GPCRs—PTGER4—skin cancer	0.0178	0.0514	CbGpPWpGaD
Bimatoprost—Cystoid macular oedema—Docetaxel—skin cancer	0.0175	0.0303	CcSEcCtD
Bimatoprost—PTGFR—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.016	0.0464	CbGpPWpGaD
Bimatoprost—PTGER1—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.0157	0.0454	CbGpPWpGaD
Bimatoprost—Uveitis—Vemurafenib—skin cancer	0.0155	0.0267	CcSEcCtD
Bimatoprost—PTGFR—Small Ligand GPCRs—PTGER4—skin cancer	0.0133	0.0384	CbGpPWpGaD
Bimatoprost—PTGER1—Small Ligand GPCRs—PTGER4—skin cancer	0.013	0.0376	CbGpPWpGaD
Bimatoprost—PTGER3—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.0123	0.0356	CbGpPWpGaD
Bimatoprost—Dinoprostone—PTGER4—skin cancer	0.0109	0.721	CrCbGaD
Bimatoprost—Common cold—Fluorouracil—skin cancer	0.00976	0.0169	CcSEcCtD
Bimatoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00921	0.0267	CbGpPWpGaD
Bimatoprost—Eyelid oedema—Imiquimod—skin cancer	0.00914	0.0158	CcSEcCtD
Bimatoprost—PTGER1—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00902	0.0261	CbGpPWpGaD
Bimatoprost—PTGFR—nipple—skin cancer	0.00807	0.134	CbGeAlD
Bimatoprost—Skin hyperpigmentation—Imiquimod—skin cancer	0.00776	0.0134	CcSEcCtD
Bimatoprost—PTGER3—connective tissue—skin cancer	0.00716	0.119	CbGeAlD
Bimatoprost—AKR1C3—nipple—skin cancer	0.00656	0.109	CbGeAlD
Bimatoprost—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—skin cancer	0.00604	0.0175	CbGpPWpGaD
Bimatoprost—PTGER1—female reproductive system—skin cancer	0.00576	0.0958	CbGeAlD
Bimatoprost—Stinging—Imiquimod—skin cancer	0.0057	0.00984	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Bleomycin—skin cancer	0.00551	0.00952	CcSEcCtD
Bimatoprost—PTGER3—female reproductive system—skin cancer	0.00505	0.084	CbGeAlD
Bimatoprost—Hypercholesterolaemia—Imiquimod—skin cancer	0.00488	0.00842	CcSEcCtD
Bimatoprost—PTGER1—head—skin cancer	0.00481	0.08	CbGeAlD
Bimatoprost—Inflammation—Imiquimod—skin cancer	0.00476	0.00822	CcSEcCtD
Bimatoprost—PTGER3—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.00465	0.0135	CbGpPWpGaD
Bimatoprost—Lacrimation—Fluorouracil—skin cancer	0.00433	0.00748	CcSEcCtD
Bimatoprost—Connective tissue disorder—Vismodegib—skin cancer	0.00432	0.00746	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Fluorouracil—skin cancer	0.00428	0.0074	CcSEcCtD
Bimatoprost—Tafluprost—PTGS2—skin cancer	0.00423	0.279	CrCbGaD
Bimatoprost—PTGER3—head—skin cancer	0.00422	0.0702	CbGeAlD
Bimatoprost—Blepharitis—Fluorouracil—skin cancer	0.00414	0.00715	CcSEcCtD
Bimatoprost—Arthritis—Vemurafenib—skin cancer	0.00404	0.00698	CcSEcCtD
Bimatoprost—PTGFR—female reproductive system—skin cancer	0.00404	0.0672	CbGeAlD
Bimatoprost—PTGFR—GPCRs, Other—SMO—skin cancer	0.0039	0.0113	CbGpPWpGaD
Bimatoprost—AKR1C3—mammalian vulva—skin cancer	0.00383	0.0637	CbGeAlD
Bimatoprost—Scotoma—Temozolomide—skin cancer	0.00364	0.00629	CcSEcCtD
Bimatoprost—Dry skin—Vemurafenib—skin cancer	0.0036	0.00622	CcSEcCtD
Bimatoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.00348	0.0101	CbGpPWpGaD
Bimatoprost—Arthritis—Imiquimod—skin cancer	0.00345	0.00595	CcSEcCtD
Bimatoprost—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.0034	0.00985	CbGpPWpGaD
Bimatoprost—PTGFR—head—skin cancer	0.00337	0.0561	CbGeAlD
Bimatoprost—PTGER3—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00335	0.00969	CbGpPWpGaD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00324	0.00559	CcSEcCtD
Bimatoprost—Cystitis noninfective—Bleomycin—skin cancer	0.0032	0.00553	CcSEcCtD
Bimatoprost—Cystitis—Bleomycin—skin cancer	0.00317	0.00547	CcSEcCtD
Bimatoprost—Stinging—Fluorouracil—skin cancer	0.00315	0.00543	CcSEcCtD
Bimatoprost—Lacrimation—Docetaxel—skin cancer	0.00313	0.0054	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Docetaxel—skin cancer	0.00309	0.00534	CcSEcCtD
Bimatoprost—Nervous system disorder—Vismodegib—skin cancer	0.00306	0.00529	CcSEcCtD
Bimatoprost—Skin disorder—Vismodegib—skin cancer	0.00304	0.00524	CcSEcCtD
Bimatoprost—PTGER3—GPCR ligand binding—PTCH2—skin cancer	0.00302	0.00875	CbGpPWpGaD
Bimatoprost—Eye irritation—Fluorouracil—skin cancer	0.00298	0.00515	CcSEcCtD
Bimatoprost—Bladder pain—Bleomycin—skin cancer	0.00296	0.00512	CcSEcCtD
Bimatoprost—PTGER3—lymph node—skin cancer	0.00295	0.0491	CbGeAlD
Bimatoprost—PTGER3—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00287	0.0083	CbGpPWpGaD
Bimatoprost—Bronchitis—Imiquimod—skin cancer	0.00278	0.00481	CcSEcCtD
Bimatoprost—Lacrimation increased—Fluorouracil—skin cancer	0.00276	0.00477	CcSEcCtD
Bimatoprost—Dyspepsia—Vismodegib—skin cancer	0.00275	0.00475	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Vismodegib—skin cancer	0.0027	0.00466	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Imiquimod—skin cancer	0.00269	0.00465	CcSEcCtD
Bimatoprost—Oedema peripheral—Vemurafenib—skin cancer	0.00268	0.00462	CcSEcCtD
Bimatoprost—Pain—Vismodegib—skin cancer	0.00267	0.00461	CcSEcCtD
Bimatoprost—Connective tissue disorder—Vemurafenib—skin cancer	0.00267	0.00461	CcSEcCtD
Bimatoprost—Burning sensation—Docetaxel—skin cancer	0.00265	0.00457	CcSEcCtD
Bimatoprost—Inflammation—Fluorouracil—skin cancer	0.00263	0.00454	CcSEcCtD
Bimatoprost—Depression—Imiquimod—skin cancer	0.00257	0.00444	CcSEcCtD
Bimatoprost—Dry eye—Temozolomide—skin cancer	0.00255	0.00441	CcSEcCtD
Bimatoprost—Eye disorder—Vemurafenib—skin cancer	0.00254	0.00439	CcSEcCtD
Bimatoprost—PTGFR—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00251	0.00725	CbGpPWpGaD
Bimatoprost—Angiopathy—Vemurafenib—skin cancer	0.00247	0.00426	CcSEcCtD
Bimatoprost—PTGER1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00245	0.00709	CbGpPWpGaD
Bimatoprost—Mediastinal disorder—Vemurafenib—skin cancer	0.00245	0.00423	CcSEcCtD
Bimatoprost—Arthritis—Bleomycin—skin cancer	0.00245	0.00423	CcSEcCtD
Bimatoprost—Sinusitis—Imiquimod—skin cancer	0.00242	0.00418	CcSEcCtD
Bimatoprost—Scotoma—Docetaxel—skin cancer	0.00242	0.00418	CcSEcCtD
Bimatoprost—Photophobia—Fluorouracil—skin cancer	0.00239	0.00413	CcSEcCtD
Bimatoprost—Erythema—Vemurafenib—skin cancer	0.00237	0.00408	CcSEcCtD
Bimatoprost—PTGFR—lymph node—skin cancer	0.00236	0.0393	CbGeAlD
Bimatoprost—Rhinitis—Imiquimod—skin cancer	0.00232	0.00401	CcSEcCtD
Bimatoprost—Pharyngitis—Imiquimod—skin cancer	0.0023	0.00397	CcSEcCtD
Bimatoprost—Connective tissue disorder—Imiquimod—skin cancer	0.00228	0.00393	CcSEcCtD
Bimatoprost—PTGFR—GPCR ligand binding—PTCH2—skin cancer	0.00226	0.00654	CbGpPWpGaD
Bimatoprost—Asthenia—Vismodegib—skin cancer	0.00224	0.00387	CcSEcCtD
Bimatoprost—Visual impairment—Imiquimod—skin cancer	0.00223	0.00386	CcSEcCtD
Bimatoprost—Eye pain—Temozolomide—skin cancer	0.00222	0.00384	CcSEcCtD
Bimatoprost—PTGER1—GPCR ligand binding—PTCH2—skin cancer	0.00221	0.0064	CbGpPWpGaD
Bimatoprost—Pruritus—Vismodegib—skin cancer	0.00221	0.00382	CcSEcCtD
Bimatoprost—PTGER3—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.0022	0.00637	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR ligand binding—MC1R—skin cancer	0.00219	0.00632	CbGpPWpGaD
Bimatoprost—AKR1C3—Arachidonic acid metabolism—PTGS2—skin cancer	0.00218	0.00631	CbGpPWpGaD
Bimatoprost—Eye disorder—Imiquimod—skin cancer	0.00217	0.00374	CcSEcCtD
Bimatoprost—Eye irritation—Docetaxel—skin cancer	0.00215	0.00372	CcSEcCtD
Bimatoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00215	0.00621	CbGpPWpGaD
Bimatoprost—Angiopathy—Imiquimod—skin cancer	0.0021	0.00363	CcSEcCtD
Bimatoprost—PTGER1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.0021	0.00608	CbGpPWpGaD
Bimatoprost—Mediastinal disorder—Imiquimod—skin cancer	0.00209	0.00361	CcSEcCtD
Bimatoprost—Cough—Vemurafenib—skin cancer	0.00206	0.00356	CcSEcCtD
Bimatoprost—Liver function test abnormal—Dactinomycin—skin cancer	0.00205	0.00354	CcSEcCtD
Bimatoprost—Erythema—Imiquimod—skin cancer	0.00202	0.00348	CcSEcCtD
Bimatoprost—Diplopia—Temozolomide—skin cancer	0.00201	0.00347	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.002	0.00345	CcSEcCtD
Bimatoprost—Lacrimation increased—Docetaxel—skin cancer	0.002	0.00345	CcSEcCtD
Bimatoprost—Rash—Vismodegib—skin cancer	0.00197	0.0034	CcSEcCtD
Bimatoprost—Dermatitis—Vismodegib—skin cancer	0.00197	0.0034	CcSEcCtD
Bimatoprost—AKR1C3—lymph node—skin cancer	0.00192	0.0319	CbGeAlD
Bimatoprost—Infection—Vemurafenib—skin cancer	0.00192	0.00331	CcSEcCtD
Bimatoprost—Inflammation—Docetaxel—skin cancer	0.0019	0.00327	CcSEcCtD
Bimatoprost—Nervous system disorder—Vemurafenib—skin cancer	0.00189	0.00327	CcSEcCtD
Bimatoprost—PTGER3—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00189	0.00546	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—RHOU—skin cancer	0.00188	0.00543	CbGpPWpGaD
Bimatoprost—Skin disorder—Vemurafenib—skin cancer	0.00188	0.00324	CcSEcCtD
Bimatoprost—Nausea—Vismodegib—skin cancer	0.00186	0.00321	CcSEcCtD
Bimatoprost—Dry skin—Temozolomide—skin cancer	0.00184	0.00318	CcSEcCtD
Bimatoprost—Palpitations—Imiquimod—skin cancer	0.00178	0.00308	CcSEcCtD
Bimatoprost—Cough—Imiquimod—skin cancer	0.00176	0.00304	CcSEcCtD
Bimatoprost—Hypertension—Imiquimod—skin cancer	0.00174	0.00301	CcSEcCtD
Bimatoprost—Chest pain—Imiquimod—skin cancer	0.00172	0.00297	CcSEcCtD
Bimatoprost—Anxiety—Imiquimod—skin cancer	0.00171	0.00296	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00171	0.00295	CcSEcCtD
Bimatoprost—Dry skin—Fluorouracil—skin cancer	0.0017	0.00293	CcSEcCtD
Bimatoprost—Dry mouth—Imiquimod—skin cancer	0.00168	0.0029	CcSEcCtD
Bimatoprost—Bronchitis—Temozolomide—skin cancer	0.00167	0.00288	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00167	0.00288	CcSEcCtD
Bimatoprost—Nasopharyngitis—Fluorouracil—skin cancer	0.00165	0.00286	CcSEcCtD
Bimatoprost—PTGFR—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00165	0.00477	CbGpPWpGaD
Bimatoprost—Infection—Imiquimod—skin cancer	0.00164	0.00282	CcSEcCtD
Bimatoprost—PTGFR—GPCR ligand binding—MC1R—skin cancer	0.00163	0.00473	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.00163	0.00473	CbGpPWpGaD
Bimatoprost—Nervous system disorder—Imiquimod—skin cancer	0.00161	0.00279	CcSEcCtD
Bimatoprost—PTGER1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00161	0.00467	CbGpPWpGaD
Bimatoprost—Upper respiratory tract infection—Temozolomide—skin cancer	0.00161	0.00278	CcSEcCtD
Bimatoprost—PTGER1—GPCR ligand binding—MC1R—skin cancer	0.0016	0.00463	CbGpPWpGaD
Bimatoprost—Skin disorder—Imiquimod—skin cancer	0.0016	0.00276	CcSEcCtD
Bimatoprost—PTGER3—GPCR ligand binding—SHH—skin cancer	0.00156	0.00451	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—PTCH2—skin cancer	0.00155	0.00449	CbGpPWpGaD
Bimatoprost—Depression—Temozolomide—skin cancer	0.00154	0.00266	CcSEcCtD
Bimatoprost—Pharyngitis—Dactinomycin—skin cancer	0.00152	0.00263	CcSEcCtD
Bimatoprost—Insomnia—Imiquimod—skin cancer	0.00149	0.00257	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00149	0.00257	CcSEcCtD
Bimatoprost—PTGER3—GPCR ligand binding—SMO—skin cancer	0.00148	0.00427	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR ligand binding—PTCH1—skin cancer	0.00148	0.00427	CbGpPWpGaD
Bimatoprost—Dyspnoea—Imiquimod—skin cancer	0.00147	0.00253	CcSEcCtD
Bimatoprost—Somnolence—Imiquimod—skin cancer	0.00146	0.00253	CcSEcCtD
Bimatoprost—Sinusitis—Temozolomide—skin cancer	0.00145	0.00251	CcSEcCtD
Bimatoprost—Dyspepsia—Imiquimod—skin cancer	0.00145	0.0025	CcSEcCtD
Bimatoprost—PTGER3—GPCR ligand binding—PTGER4—skin cancer	0.00144	0.00416	CbGpPWpGaD
Bimatoprost—Erythema—Bleomycin—skin cancer	0.00143	0.00247	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Imiquimod—skin cancer	0.00142	0.00245	CcSEcCtD
Bimatoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00141	0.00408	CbGpPWpGaD
Bimatoprost—Visual disturbance—Docetaxel—skin cancer	0.00141	0.00243	CcSEcCtD
Bimatoprost—Pain—Imiquimod—skin cancer	0.00141	0.00243	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—RHOU—skin cancer	0.0014	0.00406	CbGpPWpGaD
Bimatoprost—Asthenia—Vemurafenib—skin cancer	0.00139	0.00239	CcSEcCtD
Bimatoprost—PTGER1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00138	0.004	CbGpPWpGaD
Bimatoprost—Pharyngitis—Temozolomide—skin cancer	0.00138	0.00238	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—RHOU—skin cancer	0.00137	0.00397	CbGpPWpGaD
Bimatoprost—Oedema peripheral—Temozolomide—skin cancer	0.00137	0.00236	CcSEcCtD
Bimatoprost—Pruritus—Vemurafenib—skin cancer	0.00137	0.00236	CcSEcCtD
Bimatoprost—Connective tissue disorder—Temozolomide—skin cancer	0.00136	0.00236	CcSEcCtD
Bimatoprost—Visual impairment—Temozolomide—skin cancer	0.00134	0.00231	CcSEcCtD
Bimatoprost—Sinusitis—Fluorouracil—skin cancer	0.00134	0.00231	CcSEcCtD
Bimatoprost—Erythema—Dactinomycin—skin cancer	0.00134	0.00231	CcSEcCtD
Bimatoprost—AKR1C3—Signaling Pathways—RHOU—skin cancer	0.00133	0.00383	CbGpPWpGaD
Bimatoprost—Eye disorder—Temozolomide—skin cancer	0.0013	0.00224	CcSEcCtD
Bimatoprost—Rhinitis—Fluorouracil—skin cancer	0.00128	0.00222	CcSEcCtD
Bimatoprost—Dizziness—Vemurafenib—skin cancer	0.00128	0.0022	CcSEcCtD
Bimatoprost—Pharyngitis—Fluorouracil—skin cancer	0.00127	0.00219	CcSEcCtD
Bimatoprost—Angiopathy—Temozolomide—skin cancer	0.00126	0.00218	CcSEcCtD
Bimatoprost—Mediastinal disorder—Temozolomide—skin cancer	0.00125	0.00216	CcSEcCtD
Bimatoprost—Cough—Bleomycin—skin cancer	0.00125	0.00216	CcSEcCtD
Bimatoprost—PTGER3—GPCR downstream signaling—MC1R—skin cancer	0.00124	0.00357	CbGpPWpGaD
Bimatoprost—Liver function test abnormal—Docetaxel—skin cancer	0.00123	0.00213	CcSEcCtD
Bimatoprost—Dry skin—Docetaxel—skin cancer	0.00122	0.00211	CcSEcCtD
Bimatoprost—Chest pain—Bleomycin—skin cancer	0.00122	0.00211	CcSEcCtD
Bimatoprost—Rash—Vemurafenib—skin cancer	0.00122	0.0021	CcSEcCtD
Bimatoprost—Dermatitis—Vemurafenib—skin cancer	0.00122	0.0021	CcSEcCtD
Bimatoprost—Headache—Vemurafenib—skin cancer	0.00121	0.00209	CcSEcCtD
Bimatoprost—Erythema—Temozolomide—skin cancer	0.00121	0.00209	CcSEcCtD
Bimatoprost—Nasopharyngitis—Docetaxel—skin cancer	0.00119	0.00206	CcSEcCtD
Bimatoprost—Asthenia—Imiquimod—skin cancer	0.00118	0.00204	CcSEcCtD
Bimatoprost—Pruritus—Imiquimod—skin cancer	0.00116	0.00201	CcSEcCtD
Bimatoprost—PTGFR—GPCR ligand binding—SHH—skin cancer	0.00116	0.00337	CbGpPWpGaD
Bimatoprost—Infection—Bleomycin—skin cancer	0.00116	0.00201	CcSEcCtD
Bimatoprost—PTGFR—Signaling by GPCR—PTCH2—skin cancer	0.00116	0.00336	CbGpPWpGaD
Bimatoprost—Nausea—Vemurafenib—skin cancer	0.00115	0.00198	CcSEcCtD
Bimatoprost—PTGER1—GPCR ligand binding—SHH—skin cancer	0.00114	0.0033	CbGpPWpGaD
Bimatoprost—Vision blurred—Temozolomide—skin cancer	0.00114	0.00197	CcSEcCtD
Bimatoprost—PTGER1—Signaling by GPCR—PTCH2—skin cancer	0.00114	0.00329	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—MC1R—skin cancer	0.00112	0.00325	CbGpPWpGaD
Bimatoprost—Erythema—Fluorouracil—skin cancer	0.00111	0.00192	CcSEcCtD
Bimatoprost—PTGFR—GPCR ligand binding—PTCH1—skin cancer	0.0011	0.00319	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR ligand binding—SMO—skin cancer	0.0011	0.00319	CbGpPWpGaD
Bimatoprost—Dizziness—Imiquimod—skin cancer	0.00109	0.00188	CcSEcCtD
Bimatoprost—Vertigo—Temozolomide—skin cancer	0.00109	0.00188	CcSEcCtD
Bimatoprost—Infection—Dactinomycin—skin cancer	0.00108	0.00187	CcSEcCtD
Bimatoprost—PTGER1—GPCR ligand binding—SMO—skin cancer	0.00108	0.00313	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR ligand binding—PTCH1—skin cancer	0.00108	0.00313	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR ligand binding—PTGER4—skin cancer	0.00107	0.00311	CbGpPWpGaD
Bimatoprost—Palpitations—Temozolomide—skin cancer	0.00107	0.00184	CcSEcCtD
Bimatoprost—Cough—Temozolomide—skin cancer	0.00105	0.00182	CcSEcCtD
Bimatoprost—PTGER1—GPCR ligand binding—PTGER4—skin cancer	0.00105	0.00304	CbGpPWpGaD
Bimatoprost—Vision blurred—Fluorouracil—skin cancer	0.00105	0.00181	CcSEcCtD
Bimatoprost—Hypertension—Temozolomide—skin cancer	0.00104	0.0018	CcSEcCtD
Bimatoprost—Dyspnoea—Bleomycin—skin cancer	0.00104	0.0018	CcSEcCtD
Bimatoprost—Rash—Imiquimod—skin cancer	0.00104	0.00179	CcSEcCtD
Bimatoprost—Dermatitis—Imiquimod—skin cancer	0.00104	0.00179	CcSEcCtD
Bimatoprost—Headache—Imiquimod—skin cancer	0.00103	0.00178	CcSEcCtD
Bimatoprost—Anxiety—Temozolomide—skin cancer	0.00103	0.00177	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00102	0.00176	CcSEcCtD
Bimatoprost—Dry mouth—Temozolomide—skin cancer	0.00101	0.00174	CcSEcCtD
Bimatoprost—Pain—Bleomycin—skin cancer	0.001	0.00173	CcSEcCtD
Bimatoprost—Infection—Temozolomide—skin cancer	0.00098	0.00169	CcSEcCtD
Bimatoprost—Nausea—Imiquimod—skin cancer	0.000978	0.00169	CcSEcCtD
Bimatoprost—Nervous system disorder—Temozolomide—skin cancer	0.000968	0.00167	CcSEcCtD
Bimatoprost—Skin disorder—Temozolomide—skin cancer	0.000958	0.00165	CcSEcCtD
Bimatoprost—Chest pain—Fluorouracil—skin cancer	0.000948	0.00164	CcSEcCtD
Bimatoprost—Pain—Dactinomycin—skin cancer	0.000933	0.00161	CcSEcCtD
Bimatoprost—Rhinitis—Docetaxel—skin cancer	0.000926	0.0016	CcSEcCtD
Bimatoprost—PTGFR—GPCR downstream signaling—MC1R—skin cancer	0.000924	0.00267	CbGpPWpGaD
Bimatoprost—Pharyngitis—Docetaxel—skin cancer	0.000917	0.00158	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—PTCH2—skin cancer	0.000917	0.00265	CbGpPWpGaD
Bimatoprost—Oedema peripheral—Docetaxel—skin cancer	0.00091	0.00157	CcSEcCtD
Bimatoprost—Connective tissue disorder—Docetaxel—skin cancer	0.000908	0.00157	CcSEcCtD
Bimatoprost—PTGER1—GPCR downstream signaling—MC1R—skin cancer	0.000904	0.00262	CbGpPWpGaD
Bimatoprost—Infection—Fluorouracil—skin cancer	0.000903	0.00156	CcSEcCtD
Bimatoprost—Insomnia—Temozolomide—skin cancer	0.000892	0.00154	CcSEcCtD
Bimatoprost—Nervous system disorder—Fluorouracil—skin cancer	0.000891	0.00154	CcSEcCtD
Bimatoprost—Visual impairment—Docetaxel—skin cancer	0.00089	0.00154	CcSEcCtD
Bimatoprost—Dyspnoea—Temozolomide—skin cancer	0.00088	0.00152	CcSEcCtD
Bimatoprost—Somnolence—Temozolomide—skin cancer	0.000877	0.00151	CcSEcCtD
Bimatoprost—Dyspepsia—Temozolomide—skin cancer	0.000868	0.0015	CcSEcCtD
Bimatoprost—Eye disorder—Docetaxel—skin cancer	0.000863	0.00149	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Temozolomide—skin cancer	0.000852	0.00147	CcSEcCtD
Bimatoprost—Pain—Temozolomide—skin cancer	0.000844	0.00146	CcSEcCtD
Bimatoprost—Asthenia—Bleomycin—skin cancer	0.000839	0.00145	CcSEcCtD
Bimatoprost—PTGFR—Signaling by GPCR—MC1R—skin cancer	0.000839	0.00243	CbGpPWpGaD
Bimatoprost—Angiopathy—Docetaxel—skin cancer	0.000838	0.00145	CcSEcCtD
Bimatoprost—Mediastinal disorder—Docetaxel—skin cancer	0.000832	0.00144	CcSEcCtD
Bimatoprost—Pruritus—Bleomycin—skin cancer	0.000827	0.00143	CcSEcCtD
Bimatoprost—Insomnia—Fluorouracil—skin cancer	0.000822	0.00142	CcSEcCtD
Bimatoprost—PTGER1—Signaling by GPCR—MC1R—skin cancer	0.000821	0.00238	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR downstream signaling—PTGER4—skin cancer	0.000812	0.00235	CbGpPWpGaD
Bimatoprost—Dyspnoea—Fluorouracil—skin cancer	0.00081	0.0014	CcSEcCtD
Bimatoprost—Somnolence—Fluorouracil—skin cancer	0.000808	0.0014	CcSEcCtD
Bimatoprost—Erythema—Docetaxel—skin cancer	0.000804	0.00139	CcSEcCtD
Bimatoprost—Dyspepsia—Fluorouracil—skin cancer	0.0008	0.00138	CcSEcCtD
Bimatoprost—PTGER3—Signaling by GPCR—SHH—skin cancer	0.000799	0.00231	CbGpPWpGaD
Bimatoprost—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000785	0.00136	CcSEcCtD
Bimatoprost—Asthenia—Dactinomycin—skin cancer	0.000783	0.00135	CcSEcCtD
Bimatoprost—Pain—Fluorouracil—skin cancer	0.000777	0.00134	CcSEcCtD
Bimatoprost—PTGER3—Signaling by GPCR—SMO—skin cancer	0.000758	0.00219	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—PTCH1—skin cancer	0.000758	0.00219	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—PTGER4—skin cancer	0.000738	0.00213	CbGpPWpGaD
Bimatoprost—Rash—Bleomycin—skin cancer	0.000737	0.00127	CcSEcCtD
Bimatoprost—Dermatitis—Bleomycin—skin cancer	0.000737	0.00127	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism—PLIN2—skin cancer	0.000728	0.00211	CbGpPWpGaD
Bimatoprost—Palpitations—Docetaxel—skin cancer	0.00071	0.00123	CcSEcCtD
Bimatoprost—Asthenia—Temozolomide—skin cancer	0.000708	0.00122	CcSEcCtD
Bimatoprost—Cough—Docetaxel—skin cancer	0.000702	0.00121	CcSEcCtD
Bimatoprost—AKR1C3—Disease—CSPG4—skin cancer	0.0007	0.00203	CbGpPWpGaD
Bimatoprost—Pruritus—Temozolomide—skin cancer	0.000698	0.00121	CcSEcCtD
Bimatoprost—Nausea—Bleomycin—skin cancer	0.000695	0.0012	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—GLI2—skin cancer	0.000695	0.00201	CbGpPWpGaD
Bimatoprost—Hypertension—Docetaxel—skin cancer	0.000694	0.0012	CcSEcCtD
Bimatoprost—Rash—Dactinomycin—skin cancer	0.000688	0.00119	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—PTCH2—skin cancer	0.000685	0.00198	CbGpPWpGaD
Bimatoprost—Chest pain—Docetaxel—skin cancer	0.000684	0.00118	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00068	0.00117	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—PTCH2—skin cancer	0.000671	0.00194	CbGpPWpGaD
Bimatoprost—Dry mouth—Docetaxel—skin cancer	0.000669	0.00116	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—MC1R—skin cancer	0.000663	0.00192	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—GLI1—skin cancer	0.000653	0.00189	CbGpPWpGaD
Bimatoprost—Dizziness—Temozolomide—skin cancer	0.000652	0.00113	CcSEcCtD
Bimatoprost—Infection—Docetaxel—skin cancer	0.000652	0.00113	CcSEcCtD
Bimatoprost—Nausea—Dactinomycin—skin cancer	0.000648	0.00112	CcSEcCtD
Bimatoprost—AKR1C3—Signaling Pathways—PTCH2—skin cancer	0.000647	0.00187	CbGpPWpGaD
Bimatoprost—Nervous system disorder—Docetaxel—skin cancer	0.000643	0.00111	CcSEcCtD
Bimatoprost—Pruritus—Fluorouracil—skin cancer	0.000643	0.00111	CcSEcCtD
Bimatoprost—Skin disorder—Docetaxel—skin cancer	0.000637	0.0011	CcSEcCtD
Bimatoprost—Rash—Temozolomide—skin cancer	0.000622	0.00107	CcSEcCtD
Bimatoprost—Dermatitis—Temozolomide—skin cancer	0.000622	0.00107	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—SUFU—skin cancer	0.000619	0.00179	CbGpPWpGaD
Bimatoprost—Headache—Temozolomide—skin cancer	0.000618	0.00107	CcSEcCtD
Bimatoprost—PTGFR—GPCR downstream signaling—PTGER4—skin cancer	0.000607	0.00176	CbGpPWpGaD
Bimatoprost—Dizziness—Fluorouracil—skin cancer	0.000601	0.00104	CcSEcCtD
Bimatoprost—PTGFR—Signaling by GPCR—SHH—skin cancer	0.000598	0.00173	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR downstream signaling—PTGER4—skin cancer	0.000595	0.00172	CbGpPWpGaD
Bimatoprost—Insomnia—Docetaxel—skin cancer	0.000593	0.00102	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism—CSPG4—skin cancer	0.000587	0.0017	CbGpPWpGaD
Bimatoprost—Nausea—Temozolomide—skin cancer	0.000586	0.00101	CcSEcCtD
Bimatoprost—PTGER1—Signaling by GPCR—SHH—skin cancer	0.000585	0.00169	CbGpPWpGaD
Bimatoprost—Dyspnoea—Docetaxel—skin cancer	0.000585	0.00101	CcSEcCtD
Bimatoprost—Somnolence—Docetaxel—skin cancer	0.000583	0.00101	CcSEcCtD
Bimatoprost—Dyspepsia—Docetaxel—skin cancer	0.000578	0.000997	CcSEcCtD
Bimatoprost—Rash—Fluorouracil—skin cancer	0.000573	0.00099	CcSEcCtD
Bimatoprost—Dermatitis—Fluorouracil—skin cancer	0.000573	0.000989	CcSEcCtD
Bimatoprost—Headache—Fluorouracil—skin cancer	0.000569	0.000983	CcSEcCtD
Bimatoprost—PTGFR—Signaling by GPCR—SMO—skin cancer	0.000567	0.00164	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—PTCH1—skin cancer	0.000567	0.00164	CbGpPWpGaD
Bimatoprost—Gastrointestinal disorder—Docetaxel—skin cancer	0.000566	0.000978	CcSEcCtD
Bimatoprost—Pain—Docetaxel—skin cancer	0.000561	0.000969	CcSEcCtD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.00056	0.00162	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—SMO—skin cancer	0.000555	0.0016	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—PTCH1—skin cancer	0.000555	0.0016	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—PTGER4—skin cancer	0.000552	0.0016	CbGpPWpGaD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000548	0.00159	CbGpPWpGaD
Bimatoprost—Nausea—Fluorouracil—skin cancer	0.00054	0.000932	CcSEcCtD
Bimatoprost—PTGER1—Signaling by GPCR—PTGER4—skin cancer	0.00054	0.00156	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—GLI2—skin cancer	0.000519	0.0015	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—GLI2—skin cancer	0.000508	0.00147	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—MC1R—skin cancer	0.000496	0.00143	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—GLI2—skin cancer	0.000491	0.00142	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—GLI1—skin cancer	0.000488	0.00141	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—MC1R—skin cancer	0.000485	0.0014	CbGpPWpGaD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000482	0.00139	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—GLI1—skin cancer	0.000478	0.00138	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—SHH—skin cancer	0.000476	0.00138	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—ENO2—skin cancer	0.000476	0.00138	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—SHH—skin cancer	0.000472	0.00137	CbGpPWpGaD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000472	0.00136	CbGpPWpGaD
Bimatoprost—Asthenia—Docetaxel—skin cancer	0.000471	0.000813	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—RASA1—skin cancer	0.000469	0.00136	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—MC1R—skin cancer	0.000468	0.00135	CbGpPWpGaD
Bimatoprost—Pruritus—Docetaxel—skin cancer	0.000464	0.000802	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—SUFU—skin cancer	0.000463	0.00134	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—GLI1—skin cancer	0.000461	0.00133	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—SUFU—skin cancer	0.000453	0.00131	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—SMO—skin cancer	0.000448	0.0013	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—PTCH1—skin cancer	0.000448	0.0013	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—SUFU—skin cancer	0.000437	0.00126	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—PTGER4—skin cancer	0.000436	0.00126	CbGpPWpGaD
Bimatoprost—Dizziness—Docetaxel—skin cancer	0.000434	0.000749	CcSEcCtD
Bimatoprost—Rash—Docetaxel—skin cancer	0.000414	0.000714	CcSEcCtD
Bimatoprost—Dermatitis—Docetaxel—skin cancer	0.000413	0.000714	CcSEcCtD
Bimatoprost—Headache—Docetaxel—skin cancer	0.000411	0.00071	CcSEcCtD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000409	0.00118	CbGpPWpGaD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000401	0.00116	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—ENO2—skin cancer	0.000399	0.00115	CbGpPWpGaD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000392	0.00113	CbGpPWpGaD
Bimatoprost—Nausea—Docetaxel—skin cancer	0.00039	0.000673	CcSEcCtD
Bimatoprost—AKR1C3—Disease—FOXO4—skin cancer	0.000388	0.00112	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—FOXO4—skin cancer	0.000385	0.00111	CbGpPWpGaD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000384	0.00111	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—SHH—skin cancer	0.000353	0.00102	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—RASA1—skin cancer	0.000351	0.00102	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—SHH—skin cancer	0.000346	0.001	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—RASA1—skin cancer	0.000343	0.000994	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—SMO—skin cancer	0.000335	0.000968	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—PTCH1—skin cancer	0.000335	0.000968	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—SHH—skin cancer	0.000333	0.000965	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—RASA1—skin cancer	0.000331	0.000959	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—SMO—skin cancer	0.000328	0.000948	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—PTCH1—skin cancer	0.000328	0.000948	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—PTGER4—skin cancer	0.000326	0.000943	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—PTGER4—skin cancer	0.000319	0.000923	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—SMO—skin cancer	0.000316	0.000915	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—PTCH1—skin cancer	0.000316	0.000915	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000312	0.000902	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—PTGER4—skin cancer	0.000308	0.00089	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—FOXO4—skin cancer	0.000288	0.000833	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—FOXO4—skin cancer	0.000282	0.000815	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—ERCC2—skin cancer	0.000277	0.0008	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—FOXO4—skin cancer	0.000272	0.000786	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—TERT—skin cancer	0.000259	0.00075	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—TERT—skin cancer	0.000257	0.000744	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—ERCC2—skin cancer	0.000232	0.00067	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—NRAS—skin cancer	0.000217	0.000627	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—BRAF—skin cancer	0.000205	0.000594	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—BRAF—skin cancer	0.000204	0.000589	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—TERT—skin cancer	0.000192	0.000556	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—TERT—skin cancer	0.000188	0.000544	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—KRAS—skin cancer	0.000186	0.000539	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—TERT—skin cancer	0.000182	0.000525	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—PTGS2—skin cancer	0.000166	0.00048	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—NRAS—skin cancer	0.000162	0.000469	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—NRAS—skin cancer	0.000159	0.000459	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—HRAS—skin cancer	0.000158	0.000458	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—BRAF—skin cancer	0.000152	0.00044	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—IL6—skin cancer	0.000152	0.000439	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—BRAF—skin cancer	0.000149	0.000431	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—BRAF—skin cancer	0.000144	0.000416	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—KRAS—skin cancer	0.000139	0.000403	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—PTGS2—skin cancer	0.000139	0.000402	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—KRAS—skin cancer	0.000136	0.000395	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—NRAS—skin cancer	0.000129	0.000373	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—NRAS—skin cancer	0.000128	0.00037	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—HRAS—skin cancer	0.000118	0.000343	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—HRAS—skin cancer	0.000116	0.000336	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—IL6—skin cancer	0.000113	0.000328	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—KRAS—skin cancer	0.000111	0.000321	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—IL6—skin cancer	0.000111	0.000321	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—KRAS—skin cancer	0.00011	0.000319	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—TP53—skin cancer	9.79e-05	0.000283	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—NRAS—skin cancer	9.57e-05	0.000277	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—HRAS—skin cancer	9.44e-05	0.000273	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—NRAS—skin cancer	9.37e-05	0.000271	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—HRAS—skin cancer	9.36e-05	0.000271	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—NRAS—skin cancer	9.04e-05	0.000261	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—IL6—skin cancer	9.03e-05	0.000261	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—IL6—skin cancer	8.96e-05	0.000259	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—KRAS—skin cancer	8.23e-05	0.000238	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—KRAS—skin cancer	8.06e-05	0.000233	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—KRAS—skin cancer	7.78e-05	0.000225	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—TP53—skin cancer	7.32e-05	0.000212	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—TP53—skin cancer	7.16e-05	0.000207	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—HRAS—skin cancer	7e-05	0.000203	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—TP53—skin cancer	6.91e-05	0.0002	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—HRAS—skin cancer	6.85e-05	0.000198	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—IL6—skin cancer	6.7e-05	0.000194	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—HRAS—skin cancer	6.61e-05	0.000191	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—IL6—skin cancer	6.56e-05	0.00019	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—IL6—skin cancer	6.33e-05	0.000183	CbGpPWpGaD
